NASDAQ:BLRX BioLineRx (BLRX) Stock Price, News & Analysis $2.94 -0.16 (-5.16%) As of 02:06 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About BioLineRx Stock (NASDAQ:BLRX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get BioLineRx alerts:Sign Up Key Stats Today's Range$2.91▼$2.9950-Day Range$2.92▼$4.6452-Week Range$2.85▼$35.60Volume14,042 shsAverage Volume216,544 shsMarket Capitalization$9.79 millionP/E RatioN/ADividend YieldN/APrice Target$26.00Consensus RatingModerate Buy Company OverviewBioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.Read More… Remove Ads BioLineRx Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks48th Percentile Overall ScoreBLRX MarketRank™: BioLineRx scored higher than 48% of companies evaluated by MarketBeat, and ranked 567th out of 927 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingBioLineRx has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageBioLineRx has only been the subject of 2 research reports in the past 90 days.Read more about BioLineRx's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for BioLineRx are expected to grow in the coming year, from ($5.80) to ($5.60) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioLineRx is -0.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioLineRx is -0.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBioLineRx has a P/B Ratio of 0.40. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about BioLineRx's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted5.61% of the float of BioLineRx has been sold short.Short Interest Ratio / Days to CoverBioLineRx has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioLineRx has recently decreased by 9.47%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBioLineRx does not currently pay a dividend.Dividend GrowthBioLineRx does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted5.61% of the float of BioLineRx has been sold short.Short Interest Ratio / Days to CoverBioLineRx has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioLineRx has recently decreased by 9.47%, indicating that investor sentiment is improving significantly. News and Social Media2.0 / 5News Sentiment0.60 News SentimentBioLineRx has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for BioLineRx this week, compared to 1 article on an average week.Search InterestOnly 6 people have searched for BLRX on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added BioLineRx to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, BioLineRx insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.10% of the stock of BioLineRx is held by insiders.Percentage Held by InstitutionsOnly 1.56% of the stock of BioLineRx is held by institutions.Read more about BioLineRx's insider trading history. Receive BLRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioLineRx and its competitors with MarketBeat's FREE daily newsletter. Email Address BLRX Stock News HeadlinesBioLineRx downgraded to Hold from Buy at JonesResearchApril 2 at 8:56 AM | markets.businessinsider.comHC Wainwright Forecasts Strong Price Appreciation for BioLineRx (NASDAQ:BLRX) StockApril 2 at 1:27 AM | americanbankingnews.comTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth, your savings, and your retirement. When the dollar collapses, your savings could disappear overnight. With Trump threatening Russia with more sanctions, Russia is rushing to finalize their BRICS payment system aimed to destroy the U.S dollar.April 3, 2025 | Priority Gold (Ad)BioLineRx Ltd. (NASDAQ:BLRX) Q4 2024 Earnings Call TranscriptApril 1 at 9:20 PM | msn.comBioLineRx price target adjusted to $26 at H.C. Wainwright after reverse splitApril 1 at 1:31 AM | markets.businessinsider.comBioLineRx Ltd. (BLRX) Q4 2024 Earnings Call TranscriptMarch 31 at 11:05 AM | seekingalpha.comBioLineRx Reports 2024 Financial Results and Provides Corporate UpdateMarch 31 at 7:00 AM | prnewswire.comBioLineRx to Report 2024 Annual Results on March 31, 2025March 24, 2025 | prnewswire.comSee More Headlines BLRX Stock Analysis - Frequently Asked Questions How have BLRX shares performed this year? BioLineRx's stock was trading at $8.56 on January 1st, 2025. Since then, BLRX shares have decreased by 65.7% and is now trading at $2.94. View the best growth stocks for 2025 here. How were BioLineRx's earnings last quarter? BioLineRx Ltd. (NASDAQ:BLRX) released its quarterly earnings data on Monday, November, 25th. The biotechnology company reported ($2.80) EPS for the quarter, beating analysts' consensus estimates of ($3.20) by $0.40. BioLineRx had a negative trailing twelve-month return on equity of 163.37% and a negative net margin of 90.57%. When did BioLineRx's stock split? Shares of BioLineRx reverse split on Thursday, January 30th 2025. The 1-40 reverse split was announced on Friday, January 17th 2025. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, January 29th 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. How do I buy shares of BioLineRx? Shares of BLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of BioLineRx own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioLineRx investors own include Savara (SVRA), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Meta Platforms (META), Brainstorm Cell Therapeutics (BCLI) and Tesla (TSLA). Company Calendar Last Earnings11/25/2024Today4/03/2025Next Earnings (Estimated)5/27/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BLRX CIK1498403 Webwww.biolinerx.com Phone(728) 642-9100Fax972-8642-9101Employees40Year FoundedN/APrice Target and Rating Average Stock Price Target$26.00 High Stock Price Target$26.00 Low Stock Price Target$26.00 Potential Upside/Downside+738.7%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($8.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-60,610,000.00 Net Margins-90.57% Pretax Margin-90.57% Return on Equity-163.37% Return on Assets-34.21% Debt Debt-to-Equity Ratio2.11 Current Ratio1.52 Quick Ratio1.37 Sales & Book Value Annual Sales$21.99 million Price / Sales0.47 Cash FlowN/A Price / Cash FlowN/A Book Value$7.30 per share Price / Book0.42Miscellaneous Outstanding Shares3,329,000Free Float3,292,000Market Cap$10.32 million OptionableOptionable Beta1.39 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:BLRX) was last updated on 4/3/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNew “Trump” currency proposed in DCAfter a massive run-up – tech stocks are crashing. And as you’d suspect, the rich and powerful got out firs...Paradigm Press | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioLineRx Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioLineRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.